Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 18,885 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 18,885 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total value of $61,753.95. Following the completion of the sale, the chief executive officer now directly owns 7,085,435 shares of the company’s stock, valued at $23,169,372.45. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Puma Biotechnology Stock Down 5.5 %

Shares of NASDAQ PBYI traded down $0.18 during mid-day trading on Tuesday, reaching $3.10. 852,851 shares of the company’s stock were exchanged, compared to its average volume of 542,683. Puma Biotechnology, Inc. has a twelve month low of $2.13 and a twelve month high of $7.73. The company has a current ratio of 1.46, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of $149.54 million, a price-to-earnings ratio of 9.39 and a beta of 1.09. The business has a fifty day simple moving average of $3.99 and a 200 day simple moving average of $4.80.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.12. The firm had revenue of $43.80 million for the quarter, compared to analyst estimates of $41.53 million. Puma Biotechnology had a net margin of 6.79% and a return on equity of 35.49%. As a group, equities analysts expect that Puma Biotechnology, Inc. will post 0.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on PBYI. StockNews.com raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 12th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a report on Monday, June 3rd.

Institutional Investors Weigh In On Puma Biotechnology

Several institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC lifted its holdings in shares of Puma Biotechnology by 2.0% in the first quarter. Acadian Asset Management LLC now owns 1,956,513 shares of the biopharmaceutical company’s stock valued at $10,366,000 after purchasing an additional 39,239 shares in the last quarter. Great Point Partners LLC acquired a new position in Puma Biotechnology during the 4th quarter worth approximately $4,734,000. GSA Capital Partners LLP boosted its position in Puma Biotechnology by 143.8% during the 3rd quarter. GSA Capital Partners LLP now owns 279,629 shares of the biopharmaceutical company’s stock worth $735,000 after acquiring an additional 164,931 shares during the last quarter. Citigroup Inc. bought a new position in shares of Puma Biotechnology during the 3rd quarter worth approximately $262,000. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Puma Biotechnology by 23.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock valued at $368,000 after purchasing an additional 15,897 shares during the last quarter. 61.29% of the stock is owned by institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.